Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDXForsinkede kurser. Sist oppdatert: onsdag 13. desember
Teknisk analyse
Nyheter
Om BGBIO
Intradagsgraf
Korrelasjoner
Handelslogg
Dybdelogg
Dataeksport
Legg til interesseliste
Handle BGBIO
Sanntidssnapshot
Dato Antall dager Distributør Papir Børs Søk  
Dato Tid Selskap Overskrift
11/12-2017 07:00:26 BGBIO BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting (OBI)
  07:00:00 BGBIO BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting (Cision)
27/11-2017 09:55:00 BGBIO Hump i veien for BerGenBio (Hegnar)
  08:45:11 BGBIO BerGenBio - US Clinical Trial Update (OBI)
17/11-2017 08:00:21 BGBIO BerGenBio ASA: Exercise of employee share options and increase of capital (OBI)
  07:00:21 BGBIO BerGenBio ASA: Results for the Third Quarter 2017 (OBI)
  07:00:00 BGBIO BerGenBio ASA: Results for the Third Quarter 2017 (Cision)
16/11-2017 11:15:16 BGBIO BerGenBio to present at Jefferies 2017 London Healthcare Conferenc (OBI)
  11:15:00 BGBIO BerGenBio to present at Jefferies 2017 London Healthcare Conference (Cision)
14/11-2017 08:00:11 BGBIO BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposiu (OBI)
  08:00:00 BGBIO BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium (Cision)
10/11-2017 11:00:06 BGBIO BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast (OBI)
  11:00:00 BGBIO BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast (Cision)
01/11-2017 14:29:00 BGBIO BergenBio valgt ut til presentasjon (Hegnar)
  14:05:04 BGBIO Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting (OBI)
  14:05:00 BGBIO Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting (Cision)
24/10-2017 08:22:00 BGBIO BerGenBio oppdaterer markedet (Hegnar)
  08:00:18 BGBIO BerGenBio Announces Start of Ph II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA® for Patients with Advanced Lung Cancer (OBI)
  08:00:18 BGBIO BerGenBio Announces Start of Ph II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA® for Patients with Advanced Lung Cancer (OBI)
  08:00:00 BGBIO BerGenBio Announces Start of Ph II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA® for Patients with Advanced Lung Cancer (Cision)
19/10-2017 08:00:21 BGBIO BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (OBI)
  08:00:21 BGBIO BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (OBI)
  08:00:00 BGBIO BerGenBio Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB324 in Combination with KEYTRUDA for Patients with Advanced Breast Cancer (Cision)
18/10-2017 08:31:00 BGBIO God rekruttering av pasienter (Hegnar)
  08:00:27 BGBIO BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (OBI)
  08:00:26 BGBIO BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (OBI)
  08:00:00 BGBIO BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (Cision)
  08:00:00 BGBIO BerGenBio announces strong recruitment and encouraging safety profile for AXL Inhibitor BGB324 in a melanoma study at 9th World Congress of Melanoma (Cision)
16/10-2017 08:00:12 BGBIO BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama (OBI)
  08:00:11 BGBIO Tre kliniske studier med BGB324, BerGenBio's Selektive First-in-Class AXL Hemmer, presenteres på den 18ende verdenskonferansen om lungekreft i Yokohma (OBI)
  08:00:00 BGBIO Tre kliniske studier med BGB324, BerGenBio's Selektive First-in-Class AXL Hemmer, presenteres på den 18ende verdenskonferansen om lungekreft i Yokohma (Cision)
  08:00:00 BGBIO BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama (Cision)
12/10-2017 08:23:00 BGBIO BerGenBio skal holde presentasjon i Australia (Hegnar)
  08:00:16 BGBIO Klinisk studie med BGB324, BerGenBio's selektive First-in-Class AXL Inhibitor, presenteres på 9th World Congress of Melanoma (OBI)
  08:00:16 BGBIO Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma (OBI)
  08:00:00 BGBIO Klinisk studie med BGB324, BerGenBio's selektive First-in-Class AXL Inhibitor, presenteres på 9th World Congress of Melanoma (Cision)
  08:00:00 BGBIO Clinical Study with BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma (Cision)
28/09-2017 08:53:00 BGBIO BergenBio oppdaterer markedet (Hegnar)
  08:00:14 BGBIO BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer (OBI)
  08:00:00 BGBIO BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer (Cision)
18/08-2017 08:21:00 BGBIO Mindre minus for BerGenBio (Hegnar)
  07:00:10 BGBIO BerGenBio ASA: Results for the Second Quarter and Half year 2017 (OBI)
  07:00:00 BGBIO BerGenBio ASA: Results for the Second Quarter and Half year 2017 (Cision)
11/08-2017 08:05:15 BGBIO BerGenBio ASA: Invitation to Second Quarter and Half year 2017 Results Presentation and Webcast (OBI)
26/07-2017 08:00:06 BGBIO BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer - World R&D Summit in Boston (OBI)
  08:00:00 BGBIO BerGenBio to Present its First-In-Class, Selective AXL Inhibitor BGB324 at Precision: Lung Cancer - World R&D Summit in Boston (Cision)
13/07-2017 13:12:42 BGBIO BerGenBio ASA: Share capital increase registered (OBI)
27/06-2017 08:00:23 BGBIO BerGenBio ASA: Exercise of employee share options and increase of share capital (OBI)
26/06-2017 09:02:00 BGBIO AKSO STL Oslo Børs åpner opp (Hegnar)
  08:17:00 BGBIO BergenBio tildelt 24 millioner kroner (Hegnar)
Sidestørrelse:
Utforming |  Hjelp |  Utskrift  | Bytt til sanntid  Åpne markeder: Oslo Børs, Stockholm, København fondsbørs, Unoterte Norge
onsdag 13/12-2017 10:31:23